Loading...

Invitae Corporation

NVTANYSE
Healthcare
Medical - Diagnostics & Research
$0.02
$-0.01(-35.59%)

Invitae Corporation (NVTA) Stock Competitors & Peer Comparison

See (NVTA) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Diagnostics & Research Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
NVTA$0.02-35.59%5.4M-0.00-$5.36N/A
DHR-PB$1,261.26-0.78%916.8B146.01$8.64+0.60%
TMO$463.04-0.99%174.8B26.76$17.30+0.35%
DHR$197.09-0.04%141.1B41.84$4.71+0.60%
IDXX$535.54+0.23%43.1B49.54$10.81N/A
A$113.50-1.14%32.2B27.95$4.06+0.87%
IQV$182.45-1.83%31B26.44$6.90N/A
MTD$1,197.23-2.95%24.9B29.88$40.09N/A
DGX$170.85+2.05%19.1B20.46$8.35+1.80%
NTRA$134.58+0.69%18.4B-91.55-$1.47N/A
Showing 1 to 10 of 89 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

NVTA vs DHR-PB Comparison August 2025

NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVTA stands at 5.4M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, NVTA is priced at $0.02, while DHR-PB trades at $1,261.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVTA currently has a P/E ratio of -0.00, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, NVTA's ROE is -2.02%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, NVTA is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.Check DHR-PB's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;